Upload
Featured Recent Articles Topics Login Upload

Search Results for 'Rbv-Weeks'

Rbv-Weeks published presentations and documents on DocSlides.

C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
C-WORTHY Study Part D: grazoprevir + elbasvir + RBV in genotype 3
by UnicornLove
C-WORTHY/D. GZR + EBR + RBV. GZR + EBR + RBV. N =...
Daclatasvir + Sofosbuvir + RBV in GT3
Daclatasvir + Sofosbuvir + RBV in GT3
by sophia2
. with Advanced Liver Disease. ALLY-3+ Study. Phas...
PEG alfa-2a RBV versus
PEG alfa-2a RBV versus
by alexa-scheidler
. PEG alfa-. 2a . versus. INF RBV . APRICOT S...
SOF + RBV
SOF + RBV
by debby-jeon
SOF + RBV. Randomisation*. 1 : 1 : 1. Open-label....
SOF + EBR + GZR + RBV
SOF + EBR + GZR + RBV
by test
N = 12. N = 13. W24. W16. SOF + EBR + GZR + RBV. ...
FISSION Design Objective
FISSION Design Objective
by travis
Non . inferiority. of SOF + RBV : SVR. 12. (. 2-...
Pharmacometrics and Biostatistics Interactions at the FDA
Pharmacometrics and Biostatistics Interactions at the FDA
by byrne
Jeffry Florian, Ph.D.. Division of Pharmacometrics...
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
Andrew J. Muir, MD, MHS Chief, Division of Gastroenterology
by badra
Duke University School of Medicine. Durham, North ...
Are (exogenous) interferons
Are (exogenous) interferons
by amey
really necessary?. Peter . Ferenci. Medical Univer...
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
522432468WPbVZOeORbVcPSUZbVSTZZeWUTbVaTbVSgcbeeWbVaSWRbVObVbbVgTTWRc
by daisy
B7AB8DW10--62712/0216U28411204- f-25189455DVReWbVT...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by trish-goza
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by myesha-ticknor
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
HCV Clinical Management TRAINER(S)
HCV Clinical Management TRAINER(S)
by danika-pritchard
IAPAC African Regional Capacity-Building Hub. Bas...
Updates in Treatment of Hepatitis C
Updates in Treatment of Hepatitis C
by cheryl-pisano
Gene LeSage, MD, FACP, AGAF. Objectives. HCV epid...
OBV/PTV/r DSV Open label
OBV/PTV/r DSV Open label
by kittie-lecroy
≥ 18 years. Chronic HCV infection. Genotype 1. ...
OBV/PTV/r DSV RBV OBV/PTV/r
OBV/PTV/r DSV RBV OBV/PTV/r
by ellena-manuel
DSV . placebo. Randomisation*. Partial blind. 1...
Peginterferon alfa-2a +
Peginterferon alfa-2a +
by stefany-barnette
RBV . versus. Interferon alfa. -. 2a + RBV . ACT...
COSMOS
COSMOS
by sherrill-nordquist
SOF + SMV + RBV. SOF + SMV. Randomisation. 2 : 1 ...
Forns
Forns
by ellena-manuel
X. J . Hepatology. 2015; 63: 564-72. C-SALVAGE ...
SOF/VEL + RBV
SOF/VEL + RBV
by celsa-spraggs
N = 69. >. 18 years. Failure to SOF/VEL . or ...
SMV 12W + PEG-IFN + RBV 24-48W **
SMV 12W + PEG-IFN + RBV 24-48W **
by alexa-scheidler
SMV 24W + PEG-IFN + RBV 24-48W **. Randomisation ...
Elbasvir
Elbasvir
by calandra-battersby
+ . Grazoprevir. +/- Ribavirin in . Treatment-N...
SAPPHIRE-I
SAPPHIRE-I
by ellena-manuel
Feld JJ. NEJM . 2014;370:1594-1603. SAPPHIRE-I . ...
Ombitasvir-
Ombitasvir-
by kittie-lecroy
Paritaprevir. -. Ritonavir. . and . Dasabuvir. ...
Dore G. J
Dore G. J
by myesha-ticknor
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
PEG alfa-2a +
PEG alfa-2a +
by tawny-fly
RBV . versus. . PEG alfa-. 2a . versus. INF + R...
TURQUOISE-I
TURQUOISE-I
by marina-yarberry
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...
C-SCAPE
C-SCAPE
by tawny-fly
Design. C-SCAPE . Study. : . grazoprevir. ± . e...
Dore G. J
Dore G. J
by pasty-toler
Hepatol. 2016; 64:19-28. MALACHITE. TVR + PEG-IF...
Reddy KR. Lancet Infect Dis. 2015;15:27-35
Reddy KR. Lancet Infect Dis. 2015;15:27-35
by natalia-silvester
ATTAIN. SMV + TVR placebo. + PEG-IFN + RBV. TVR ...
State of the Art Therapy for HCV
State of the Art Therapy for HCV
by liane-varnes
Last Updated: February . 21, 2014. Robert G. Gish...
Direct Acting Antivirals: What are they? What is their pl
Direct Acting Antivirals: What are they? What is their pl
by tawny-fly
Mark Sulkowski, MD. Associate Professor of Medici...
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
Étude PEARL III : ABT-450/r/267 + ABT-333 ± RBV
by tatiana-dople
dans les génotypes 1b naïfs de traitement . (1)...
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
3D (Paritaprevir-Ritonavir-Ombitasvir + Dasabuvir) + RBV in
by yoshiko-marsland
TURQUOISE-II. Phase 3. . Treatment. Naïve and ...
Future HCV Treatment Paradigms
Future HCV Treatment Paradigms
by kittie-lecroy
Mark Sulkowski, MD . Professor of Medicine. Medic...
Edited by
Edited by
by celsa-spraggs
Morris Sherman MD . BCh. PhD FRCP(C) . Associate...
3 D (Paritaprevir
3 D (Paritaprevir
by myesha-ticknor
-Ritonavir. -Ombitasvir . + Dasabuvir) . + RBV in...
C-SCAPE
C-SCAPE
by pasty-toler
Design. C-SCAPE . Study. : . grazoprevir. ± . e...
SIRIUS
SIRIUS
by tawny-fly
Placebo. LDV/SOF + placebo. Randomisation*. 1 : 1...
TURQUOISE-I
TURQUOISE-I
by natalia-silvester
OBV/PTV/r + . DSV . + RBV. OBV/PTV/r + . DSV . + ...